|
Article | Patient characteristics | Tumour characteristics | Interferon (IFN) therapy |
Outcome |
Author (year of publication) | Gender, age | Comorbidity | Tumours ze (cm) | Location | HPV type | Initial therapy (earlier surgical interventions Yes/No) | Followed by | Type | Way of administration | Dose | Frequency | Length | Adverse effects |
|
Tan et al. (2010) [15] | F, 21 | immuno-therapy (SLE) | | Vulvar | 6 | Radical resection and IFN (Y) | none | | — | — | — | 6 months | — | CR (2 years of follow-up) |
Mudrikova et al. (2008) [10] | M, 44 | HIV | — | Perineal and perianal | 6 | IFN + local cidofovir* (Y) | none | Pegylated | Subcutane | — | — | — | None | Pt died |
De Toma et al. (2006) [21] | M, 46 | None | | Perianal | 6 | Surgical local excision** (N) | IFN | — | Systemic | 3 MU | — | — | — | CR (3 years of follow-up) |
Antony et al. (2003) [11] | M, 61 | Therapy-resistant erythroderma | — | Perineum involving the penis | 16 | IFN* (N) | Chemo-therapy | | Subcutane | 9 MU | 3/wk | — | Neutropenia - could be chemoinduced | No effect, patient died of septicaemia |
Geusau et al. (2000) [12] | M, 40 | None | — | Perianal | 6 | IFN (Y) | Partial chirurgic resection | | Intralesional | 10 MU | 3/wk | 28 months | — | CR after 12 m |
Grassegger et al. (1994) [13] | M, 42 | None | — | Genital/ perianal | 6 | Surgery (Y) | IFN | | Subcutane | 2 MU | 6/wk every 2nd wk | 3 months | — | Recurrence after 2 y |
Tsambaos et al. (1994) [16] | M, 39 | None | 8,7 × 7,3 × 5,6 | Inguinal | 6, 11 | IFN* (N) | Podofyline | | Intralesional | 9 MU | 3/wk | — | Fever, myalgias, chills | CR after 5 months (16 months follow-up) |
Gritsch et al. (1989) [14] | M, 29 | None | 3,5 × 4 | Perianal | — | IFN (Y) | Partial chirurgic resection | | Subcutane | 6 MU | 7/wk | 30 days | — | Progression, patient died of pneumonia |
|